We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
Cap. Flow
+$1.08B
Cap. Flow %
13.6%
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$440M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$270M
3
AFIB
Acutus Medical Inc
AFIB
+$166M
4
ACET icon
Adicet Bio
ACET
+$95.1M
5
TBPH icon
Theravance Biopharma
TBPH
+$68.6M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$119M
2
CI icon
Cigna
CI
+$82.5M
3
NTRA icon
Natera
NTRA
+$64.2M
4
ALEC icon
Alector
ALEC
+$52.6M
5
GKOS icon
Glaukos
GKOS
+$46.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 0.63%
3 Technology 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
126
Cartesian Therapeutics
RNAC
$216M
$5.19M 0.07%
69,796
– –
MYOV
127
DELISTED
Myovant Sciences Ltd.
MYOV
$5.12M 0.06%
+364,500
New +$6.78M
ARNA
128
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.99M 0.06%
66,700
– –
ACAD icon
129
Acadia Pharmaceuticals
ACAD
$4.46B
$4.41M 0.06%
+107,000
New +$4.62M
SYBX
130
DELISTED
Synlogic
SYBX
$4.1M 0.05%
135,333
– –
KYMR icon
131
Kymera Therapeutics
KYMR
$8.68B
$3.23M 0.04%
+100,000
New +$3.05M
OBSV
132
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.23M 0.04%
1,303,000
-1,302,531
-50% -$3.72M
IFRX icon
133
InflaRx
IFRX
$245M
$2.89M 0.04%
678,525
– –
MIST icon
134
Milestone Pharmaceuticals
MIST
$127M
$2.82M 0.04%
+385,791
New +$2.77M
ANAB icon
135
AnaptysBio
ANAB
$1.52B
$2.66M 0.03%
180,442
-195,358
-52% -$3.52M
RNAM
136
DELISTED
Avidity Biosciences
RNAM
$1.8M 0.02%
63,860
-136,140
-68% -$3.93M
PPBT
137
Purple Biotech
PPBT
$1.3M
$1.53M 0.02%
1,731
– –
CRIS icon
138
Curis
CRIS
$9.67M
$1.45M 0.02%
3,104
– –
NBRV
139
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.41M 0.02%
10,578
-8,000
-43% -$1.34M
BMY.RT
140
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$900K 0.01%
400,000
+50,000
+14% +$143K
MYOV
141
CALL
DELISTED
Myovant Sciences Ltd.
MYOV
$703K 0.01%
+50,000
New +$930K
CALT
142
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$425K 0.01%
17,696
-207,304
-92% -$4.83M
BLRX
143
BioLineRX
BLRX
$12.3M
$114K ﹤0.01%
1,731
– –
ABBV icon
144
CALL
AbbVie
ABBV
$471B
– –
-100,000
Closed -$9.82M
AGIO icon
145
CALL
Agios Pharmaceuticals
AGIO
$2.08B
– –
-100,000
Closed -$5.35M
ARVN icon
146
Arvinas
ARVN
$525M
– –
-29,400
Closed -$986K
ARWR icon
147
Arrowhead Research
ARWR
$11.9B
– –
-68,100
Closed -$2.94M
CI icon
148
Cigna
CI
$79B
– –
-439,700
Closed -$82.5M
CRBP icon
149
PUT
Corbus Pharmaceuticals
CRBP
$167M
– –
-11,667
Closed -$2.94M
GKOS icon
150
Glaukos
GKOS
$9.19B
– –
-1,211,000
Closed -$46.5M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2020 Portfolio in Review

As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.

  • OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
  • OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
  • OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
  • OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
  • OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
  • OrbiMed opened 28 new positions and closed 20 in Q3 2020.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.